StreetInsider.com News Articles

Oppenheimer on Pharming Group (PHAR): 'Ruconest Performance Exceeds Expectations'

Wed, 28 Oct 2026 04:30:34 -0400

Oppenheimer analyst Jeff Jones reiterated an Outperform rating and $39.00 price target on Pharming Group (NASDAQ: PHAR).

The analyst comments "PHAR reported 3Q results Tuesday morning consistent with preliminary results pre-reported last week (Note). Highlights include: stronger than anticipated Ruconest performance, continued Joenja growth, and improving operational leverage. Strong revenue growth seen for Ruconest, in part attributed to channel inventory timing, with demand appearing to stabilize with strong patient retention. Meanwhile, the Joenja franchise continues to perform well across both US and international markets, with additional growth catalysts emerging from recently approved pediatric dosing and ongoing geographic expansion. Management reiterated expectations

Form 6-K Pharming Group N.V. For: Oct 27

Tue, 27 Oct 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20261027/27236618.html

Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

Tue, 27 Oct 2026 02:00:00 -0400

Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectations
RUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025, reflecting demand stabilization and seasonal inventory increase
Joenja® (leniolisib) revenue increased by 58% to US$23.8 million, compared to third quarter 2025, reflecting strong U.S. and international demand
Tightened 2026 total revenue guidance to US$380 million - US$390 million from prior US$375 million - US$395 million
Operating profit increased by 89% to US$29.9 million, compared to third quarter 2025
Generated US$32.4 million in cash flow from operations

Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

Tue, 27 Oct 2026 02:00:00 -0400

Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectations
RUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025, reflecting demand stabilization and seasonal inventory increase
Joenja® (leniolisib) revenue increased by 58% to US$23.8 million, compared to third quarter 2025, reflecting strong U.S. and international demand
Tightened 2026 total revenue guidance to US$380 million - US$390 million from prior US$375 million - US$395 million
Operating profit increased by 89% to US$29.9 million, compared to third quarter 2025
Generated US$32.4 million in cash flow from operations

Form 6-K Pharming Group N.V. For: Oct 22

Thu, 22 Oct 2026 07:06:00 -0400
si-local-file:///var/storage/secattach/20261022/27218861.html

Pharming Group N.V. (PHAR) Reports Q3 results; offers guidance

Thu, 22 Oct 2026 03:10:50 -0400

Pharming Group N.V. (NASDAQ: PHAR) reported Q3 Revenue for the quarter at $117.6 million versus the consensus estimate of $103.54 million.
GUIDANCE:
Pharming Group N.V. sees FY2026 revenue of $380-390 million, versus the consensus of $383.4 million.
For earnings history and earnings-related data on Pharming Group N.V. (PHAR) click here.

Pharming Group N.V. (PHAR) Reports Q3 results; offers guidance

Thu, 22 Oct 2026 03:10:50 -0400

Pharming Group N.V. (NASDAQ: PHAR) reported Q3 Revenue for the quarter at $117.6 million versus the consensus estimate of $103.54 million.
GUIDANCE:
Pharming Group N.V. sees FY2026 revenue of $380-390 million, versus the consensus of $383.4 million.
For earnings history and earnings-related data on Pharming Group N.V. (PHAR) click here.

Pharming Group announces third quarter 2026 revenues above market expectations

Thu, 22 Oct 2026 01:00:00 -0400

Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025
Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third quarter 2025
Tightened 2026 total revenue guidance to US$380 million - US$390 million from prior US$375 million - US$395 million
Full third quarter financial results and business update brought forward to October 27, 2026; conference call and webcast for analysts and investors to follow at 13:30 CET/08:30 EDT

Leiden, the Netherlands, October 22, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune

Pharming Group announces third quarter 2026 revenues above market expectations

Thu, 22 Oct 2026 01:00:00 -0400

Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025
Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third quarter 2025
Tightened 2026 total revenue guidance to US$380 million - US$390 million from prior US$375 million - US$395 million
Full third quarter financial results and business update brought forward to October 27, 2026; conference call and webcast for analysts and investors to follow at 13:30 CET/08:30 EDT

Leiden, the Netherlands, October 22, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune

Form 6-K Pharming Group N.V. For: Oct 14

Wed, 14 Oct 2026 06:04:00 -0400
si-local-file:///var/storage/secattach/20261014/27183231.html

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Wed, 14 Oct 2026 02:00:00 -0400

First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation
Leniolisib was well-tolerated, with benefits observed across multiple measures of immune dysregulation, including improvement in lymphoproliferation and positive trends in lung and liver disease markers
All participants who completed the study elected to continue receiving treatment in a long-term extension study

Leiden, the Netherlands, October 14, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today presented positive topline data from its

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Wed, 14 Oct 2026 02:00:00 -0400

First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation
Leniolisib was well-tolerated, with benefits observed across multiple measures of immune dysregulation, including improvement in lymphoproliferation and positive trends in lung and liver disease markers
All participants who completed the study elected to continue receiving treatment in a long-term extension study

Leiden, the Netherlands, October 14, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today presented positive topline data from its

Form 6-K Pharming Group N.V. For: Sep 29

Tue, 29 Sep 2026 06:40:00 -0400
si-local-file:///var/storage/secattach/20260929/27117027.html

Pharming CEO steps down; interim co-CEOs named

Tue, 29 Sep 2026 01:00:09 -0400

Pharming Group N.V. (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announced that Fabrice Chouraqui has stepped down as Chief Executive Officer and Executive Director by mutual agreement with the Board of Directors, effective immediately.

The Board has appointed Chief Commercial Officer Leverne Marsh and Chief Financial Officer Kenneth Lynard as Interim Co-CEOs. Marsh will oversee patient-focused operations, while Lynard will lead global corporate functions. The Board has begun a formal search for a permanent CEO.

According to the announcement, the Board and Chouraqui concluded their views on executing the company's strategic priorities were not sufficiently aligned, prompting the leadership change.

Board Chairman Richard Peters

Pharming announces CEO transition

Tue, 29 Sep 2026 01:00:00 -0400

Leiden, the Netherlands, September 29, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. Chouraqui will step down as Chief Executive Officer and Executive Director, with immediate effect.

To ensure continuity of leadership, the Board of Directors has appointed Mrs. Leverne Marsh, Chief Commercial Officer, and Mr. Kenneth Lynard, Chief Financial Officer, as Interim Co-CEOs, effective immediately. Mrs. Marsh will lead the patient-focused operations while Mr. Lynard will lead the global corporate functions. The Board

Pharming announces CEO transition

Tue, 29 Sep 2026 01:00:00 -0400

Leiden, the Netherlands, September 29, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. Chouraqui will step down as Chief Executive Officer and Executive Director, with immediate effect.

To ensure continuity of leadership, the Board of Directors has appointed Mrs. Leverne Marsh, Chief Commercial Officer, and Mr. Kenneth Lynard, Chief Financial Officer, as Interim Co-CEOs, effective immediately. Mrs. Marsh will lead the patient-focused operations while Mr. Lynard will lead the global corporate functions. The Board

Form 6-K Pharming Group N.V. For: Sep 25

Fri, 25 Sep 2026 11:12:00 -0400
si-local-file:///var/storage/secattach/20260925/27105302.html

FDA accepts Pharming's sNDA for Joenja in lower-weight children

Fri, 25 Sep 2026 10:30:18 -0400

Pharming Group (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application seeking approval for lower doses of Joenja® (leniolisib) for children aged 4 years and older who weigh between 13 kg and 27 kg with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.

The FDA granted the application Priority Review and assigned a Prescription Drug User Fee Act target action date of January 30, 2027. The FDA grants Priority Review to applications for medicines that, if approved, would offer significant improvements in the effectiveness or safety of

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

Fri, 25 Sep 2026 10:30:00 -0400

If approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more
Decision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least 27 kg
PDUFA target action date of January 30, 2027

Leiden, the Netherlands, September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for lower

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

Fri, 25 Sep 2026 10:30:00 -0400

If approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more
Decision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least 27 kg
PDUFA target action date of January 30, 2027

Leiden, the Netherlands, September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for lower

Canaccord Reiterates Buy Rating on Pharming Group (PHAR)

Wed, 23 Sep 2026 06:42:27 -0400

Canaccord analyst Whitney Ijem reiterated a Buy rating and $38.00 price target on Pharming Group (NASDAQ: PHAR).
The analyst commented: 'Overnight, PHAR announced positive topline Phase II data for Joenja (leniolisib) in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kδ signaling. The study showed clinical improvements across measures of immune dysregulation, including lymphoproliferative disease, with a mean 26.4% (n=13) reduction in spleen volume and reductions in index lesion size. This is consistent with the spleen-volume benefit seen with Joenja's approved APDS indication where Joenja showed a 26.68% mean reduction in 3D spleen volume at week 12 (n=19) versus

Form 6-K Pharming Group N.V. For: Sep 22

Tue, 22 Sep 2026 06:03:00 -0400
si-local-file:///var/storage/secattach/20260922/27087124.html

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

Tue, 22 Sep 2026 01:00:00 -0400

Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation
Separately, Pharming expects to report topline results from a Phase II trial of leniolisib in CVID in Q4 2026

Leiden, the Netherlands, September 22, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that a late-breaking abstract highlighting positive topline data from its Phase II trial with leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kd signaling has been

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

Tue, 22 Sep 2026 01:00:00 -0400

Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation
Separately, Pharming expects to report topline results from a Phase II trial of leniolisib in CVID in Q4 2026

Leiden, the Netherlands, September 22, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that a late-breaking abstract highlighting positive topline data from its Phase II trial with leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kd signaling has been

Form 6-K Pharming Group N.V. For: Sep 11

Fri, 11 Sep 2026 14:59:00 -0400
si-local-file:///var/storage/secattach/20260911/27052571.html